Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

riociguat 0.5 MG Oral Tablet

Known as: RIOCIGUAT 0.5MG TAB, RIOCIGUAT 0.5MG TAB,UD [VA Product], RIOCIGUAT 0.5MG TAB UD 
 
National Institutes of Health

Related topics

Related topics

4 relations
Guanylate Cyclase Stimulators [MoA]Hypertensive diseaseOral Tabletriociguat

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
NT - 483 - 2018 - Riociguat - NAT-JUS - TJMG
 
Is this relevant?
2015
2015
The sGC-stimulator Riociguat for the treatment of Raynaud's phenomenon: A single-dose, double-blind, randomized, placebo-controlled cross-over study (DIGIT)
Background Raynaud’s phenomenon (RP) is a coldor stress-triggered digital ischemia caused by vasoconstriction in the digital… Expand
Is this relevant?
2015
2015
РИОЦИГУАТ – ПЕРВЫЙ ЛЕКАРСТВЕННЫЙ ПРЕПАРАТ ИННОВАЦИОННОГО КЛАССА СТИМУЛЯТОРОВ ГУАНИЛАТЦИКЛАЗЫ ДЛЯ ЛЕЧЕНИЯ БОЛЬНЫХ ЛЕГОЧНОЙ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ
Summary Pulmonary arterial hypertension (PAH) drug therapy including prostanoids, endothelin receptor antagonists, type 5… Expand
Is this relevant?
2013
2013
Neuer Weg zur Therapie der pulmonalen Hypertonie
Fur die Therapie der pulmonalen Hypertonie (PH) steht mit den loslichen Guanylatcyclase-Stimulatoren eine neue Gruppe von… Expand
Is this relevant?
2013
2013
Riociguat zur Therapie der inoperablen chronisch thromboembolischen pulmonalen Hypertonie: Eine randomisierte, doppelblinde, placebokontrollierte Phase-III-Studie (CHEST-1)
 
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE